Cost of Revenue Comparison: Viatris Inc. vs Exelixis, Inc.

Cost of Revenue: A Tale of Two Companies

Viatris Inc. vs. Exelixis, Inc.

In the ever-evolving pharmaceutical landscape, understanding cost structures is crucial. This chart offers a fascinating glimpse into the cost of revenue trends for Viatris Inc. and Exelixis, Inc. over the past decade. From 2014 to 2023, Viatris Inc. consistently reported higher costs, peaking in 2021 with a staggering 12.3 billion dollars. In contrast, Exelixis, Inc. showed a more modest increase, with costs rising from 2 million dollars in 2014 to 72.5 million dollars in 2023.

Viatris Inc.'s cost of revenue is approximately 100 times that of Exelixis, Inc., highlighting the scale and operational differences between the two. This disparity underscores the diverse strategies and market positions within the pharmaceutical industry. As we move forward, these insights can guide investors and stakeholders in making informed decisions.